Drug intelligence / Profile preview

18F-N230A

Development stage: Unknown
Lead developer: Peking University First Hospital
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals
Administration: Intravenous

Overview

18F-N230A is an investigational radiolabeled positron emission tomography (PET) imaging probe targeting Nectin cell adhesion molecule 4 (Nectin-4). Developed by Peking University First Hospital, 18F-N230A is designed to noninvasively evaluate and quantify Nectin-4 expression in tumors. It is being clinically evaluated in PET/CT imaging studies to differentiate between renal cell carcinoma (RCC) and renal pelvic urothelial carcinoma in patients with suspected or confirmed renal tumors, supporting preoperative diagnosis and clinical decision-making.

Other names: [18F]-N230A[18F]N230A

Targets

PVRL4 (Nectin cell adhesion molecule 4)

Beyond the preview

Go deeper on 18F-N230A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 18F-N230A.